Synergistic role of 5-azacytidine and ascorbic acid in directing cardiosphere derived cells to cardiomyocytes in vitro by downregulating Wnt signaling pathway via phosphorylation of β-catenin

PLoS One. 2017 Nov 30;12(11):e0188805. doi: 10.1371/journal.pone.0188805. eCollection 2017.

Abstract

Background: Cardiosphere derived cells (CDCs) represent a valuable source in stem cell based therapy for cardiovascular diseases, yet poor differentiation rate hinders the transplantation efficiency. The aim of this study is to check the ability of 5-Azacytidine (Aza) alone and in combination with ascorbic acid (Aza+AA) in delineating CDCs to cardiomyogenesis and the underlying Wnt signaling mechanism in induced differentiation.

Methods: CDCs were treated with Aza and Aza+AA for a period of 14 days to examine the expression of cardiac specific markers and Wnt downstream regulators by immunofluorescence, real time PCR and western blot.

Results: Results revealed that Aza+AA induced efficient commitment of CDCs to cardiomyogenic lineage. Immunofluorescence analysis showed significant augment for Nkx 2.5, GATA 4 and α-Sarcomeric actinin markers in Aza+AA group than control group (p = 0.0118, p = 0.009 and p = 0.0091, respectively). Relative upregulation of cardiac markers, Nkx 2.5 (p = 0.0156), GATA 4 (p = 0.0087) and down regulation of Wnt markers, β-catenin (p = 0.0107) and Cyclin D1 (p = 0. 0116) in Aza+AA group was revealed by RNA expression analysis. Moreover, the Aza+AA induced prominent expression of GATA 4, α-Sarcomeric actinin and phospho β-catenin while non phospho β-catenin and Cyclin D1 expression was significantly suppressed as displayed in protein expression analysis. Generation of spontaneous beating in Aza+AA treated CDCs further reinforced that Aza+AA accelerates the cardiomyogenic potential of CDCs.

Conclusion: Combined treatment of Aza along with AA implicit in inducing cardiomyogenic potential of CDCs and is associated with down regulating Wnt signaling pathway. Altogether, CDCs represent a valuable tool for the treatment of cardiovascular disorders.

MeSH terms

  • Animals
  • Ascorbic Acid / pharmacology*
  • Azacitidine / pharmacology*
  • Cell Differentiation / drug effects
  • Cell Proliferation / drug effects
  • Down-Regulation / drug effects*
  • Drug Synergism
  • Heart / drug effects*
  • In Vitro Techniques
  • Male
  • Phosphorylation
  • Rats
  • Rats, Wistar
  • Wnt Signaling Pathway / drug effects*
  • beta Catenin / metabolism*

Substances

  • beta Catenin
  • Azacitidine
  • Ascorbic Acid

Grants and funding

The authors are thankful to Department of Science and Technology, New Delhi, India for the financial support under DST-INSPIRE Fellowship (No: DST/INSPIRE Fellowship/2012/143) granted to RSM. We acknowledge the financial support from MHRDCEMA F.NO-5-3/2015-TS VII and BUILDER program BT/PR12153/INF/22/200/2014 to AD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.